STOCK TITAN

[8-K] Surmodics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

On 8 Aug 2025 Surmodics, Inc. (SRDX) filed a Form 8-K to furnish a press release announcing its financial results for the quarter ended 30 Jun 2025. The press release is attached as Exhibit 99.1, but the filing itself contains no revenue, EPS, balance-sheet or guidance figures. The disclosure falls under Item 2.02 (Results of Operations and Financial Condition) and is expressly marked as “furnished,” not “filed,” which limits Section 18 Exchange Act liability. Aside from the exhibit list and standard representations, the document offers no additional financial data or strategic commentary.

Il 8 agosto 2025 Surmodics, Inc. (SRDX) ha presentato un Modulo 8-K per fornire un comunicato stampa che annuncia i risultati finanziari del trimestre terminato il 30 giugno 2025. Il comunicato stampa è allegato come Exhibit 99.1, ma il documento stesso non contiene dati su ricavi, utili per azione, bilancio o previsioni. La comunicazione rientra nella voce 2.02 (Risultati Operativi e Condizione Finanziaria) ed è espressamente indicata come “fornita” e non “depositata”, limitando così la responsabilità ai sensi della Sezione 18 del Exchange Act. A parte l’elenco degli allegati e le dichiarazioni standard, il documento non offre ulteriori dati finanziari o commenti strategici.

El 8 de agosto de 2025, Surmodics, Inc. (SRDX) presentó un Formulario 8-K para proporcionar un comunicado de prensa que anuncia sus resultados financieros del trimestre concluido el 30 de junio de 2025. El comunicado está adjunto como el Anexo 99.1, pero el documento en sí no contiene cifras de ingresos, BPA, balance o previsiones. La divulgación corresponde al Punto 2.02 (Resultados Operativos y Condición Financiera) y está marcada expresamente como “proporcionada” y no “presentada”, lo que limita la responsabilidad bajo la Sección 18 del Exchange Act. Aparte de la lista de anexos y las representaciones estándar, el documento no ofrece datos financieros adicionales ni comentarios estratégicos.

2025년 8월 8일 Surmodics, Inc. (SRDX)는 2025년 6월 30일 종료된 분기 재무 결과를 발표하는 보도자료를 제공하기 위해 Form 8-K를 제출했습니다. 보도자료는 Exhibit 99.1로 첨부되어 있으나, 제출 문서 자체에는 매출, 주당순이익, 재무상태표 또는 가이던스 수치가 포함되어 있지 않습니다. 이 공시는 항목 2.02(영업실적 및 재무상태)에 해당하며, 명시적으로 “제공됨(furnished)”으로 표시되어 있어 Exchange Act 섹션 18의 책임이 제한됩니다. 첨부 목록과 표준 진술 외에는 추가 재무 데이터나 전략적 코멘트가 포함되어 있지 않습니다.

Le 8 août 2025, Surmodics, Inc. (SRDX) a déposé un formulaire 8-K pour fournir un communiqué de presse annonçant ses résultats financiers pour le trimestre clos le 30 juin 2025. Le communiqué est joint en tant qu’Exhibit 99.1, mais le dépôt lui-même ne contient aucune donnée sur le chiffre d’affaires, le BPA, le bilan ou les prévisions. La divulgation relève de l’Item 2.02 (Résultats d’Exploitation et Situation Financière) et est expressément marquée comme « fournie » et non « déposée », ce qui limite la responsabilité en vertu de la Section 18 du Exchange Act. Hormis la liste des annexes et les déclarations standard, le document n’offre aucune donnée financière supplémentaire ni commentaire stratégique.

Am 8. August 2025 reichte Surmodics, Inc. (SRDX) ein Formular 8-K ein, um eine Pressemitteilung zu den Finanzergebnissen für das Quartal zum 30. Juni 2025 bereitzustellen. Die Pressemitteilung ist als Anlage 99.1 beigefügt, enthält jedoch im eigentlichen Dokument keine Angaben zu Umsatz, Gewinn je Aktie, Bilanz oder Prognosen. Die Offenlegung fällt unter Punkt 2.02 (Ergebnisse der Geschäftstätigkeit und Finanzlage) und ist ausdrücklich als „bereitgestellt“ und nicht „eingereicht“ gekennzeichnet, was die Haftung nach Abschnitt 18 des Exchange Act einschränkt. Abgesehen von der Anlagenliste und den Standardangaben enthält das Dokument keine weiteren finanziellen Daten oder strategischen Kommentare.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine 8-K furnishes earnings press release; no numbers disclosed; neutral investor impact.

This Form 8-K simply notifies investors that Surmodics has released its quarter-ended 30 Jun 2025 results via Exhibit 99.1. Because the exhibit content is not included here, investors gain no visibility into revenue trends, profitability, or guidance. The information is also classified as “furnished,” further underscoring its procedural nature. In the absence of hard data, the filing neither alters valuation assumptions nor signals material risk or opportunity. Impact is best described as administrative.

Il 8 agosto 2025 Surmodics, Inc. (SRDX) ha presentato un Modulo 8-K per fornire un comunicato stampa che annuncia i risultati finanziari del trimestre terminato il 30 giugno 2025. Il comunicato stampa è allegato come Exhibit 99.1, ma il documento stesso non contiene dati su ricavi, utili per azione, bilancio o previsioni. La comunicazione rientra nella voce 2.02 (Risultati Operativi e Condizione Finanziaria) ed è espressamente indicata come “fornita” e non “depositata”, limitando così la responsabilità ai sensi della Sezione 18 del Exchange Act. A parte l’elenco degli allegati e le dichiarazioni standard, il documento non offre ulteriori dati finanziari o commenti strategici.

El 8 de agosto de 2025, Surmodics, Inc. (SRDX) presentó un Formulario 8-K para proporcionar un comunicado de prensa que anuncia sus resultados financieros del trimestre concluido el 30 de junio de 2025. El comunicado está adjunto como el Anexo 99.1, pero el documento en sí no contiene cifras de ingresos, BPA, balance o previsiones. La divulgación corresponde al Punto 2.02 (Resultados Operativos y Condición Financiera) y está marcada expresamente como “proporcionada” y no “presentada”, lo que limita la responsabilidad bajo la Sección 18 del Exchange Act. Aparte de la lista de anexos y las representaciones estándar, el documento no ofrece datos financieros adicionales ni comentarios estratégicos.

2025년 8월 8일 Surmodics, Inc. (SRDX)는 2025년 6월 30일 종료된 분기 재무 결과를 발표하는 보도자료를 제공하기 위해 Form 8-K를 제출했습니다. 보도자료는 Exhibit 99.1로 첨부되어 있으나, 제출 문서 자체에는 매출, 주당순이익, 재무상태표 또는 가이던스 수치가 포함되어 있지 않습니다. 이 공시는 항목 2.02(영업실적 및 재무상태)에 해당하며, 명시적으로 “제공됨(furnished)”으로 표시되어 있어 Exchange Act 섹션 18의 책임이 제한됩니다. 첨부 목록과 표준 진술 외에는 추가 재무 데이터나 전략적 코멘트가 포함되어 있지 않습니다.

Le 8 août 2025, Surmodics, Inc. (SRDX) a déposé un formulaire 8-K pour fournir un communiqué de presse annonçant ses résultats financiers pour le trimestre clos le 30 juin 2025. Le communiqué est joint en tant qu’Exhibit 99.1, mais le dépôt lui-même ne contient aucune donnée sur le chiffre d’affaires, le BPA, le bilan ou les prévisions. La divulgation relève de l’Item 2.02 (Résultats d’Exploitation et Situation Financière) et est expressément marquée comme « fournie » et non « déposée », ce qui limite la responsabilité en vertu de la Section 18 du Exchange Act. Hormis la liste des annexes et les déclarations standard, le document n’offre aucune donnée financière supplémentaire ni commentaire stratégique.

Am 8. August 2025 reichte Surmodics, Inc. (SRDX) ein Formular 8-K ein, um eine Pressemitteilung zu den Finanzergebnissen für das Quartal zum 30. Juni 2025 bereitzustellen. Die Pressemitteilung ist als Anlage 99.1 beigefügt, enthält jedoch im eigentlichen Dokument keine Angaben zu Umsatz, Gewinn je Aktie, Bilanz oder Prognosen. Die Offenlegung fällt unter Punkt 2.02 (Ergebnisse der Geschäftstätigkeit und Finanzlage) und ist ausdrücklich als „bereitgestellt“ und nicht „eingereicht“ gekennzeichnet, was die Haftung nach Abschnitt 18 des Exchange Act einschränkt. Abgesehen von der Anlagenliste und den Standardangaben enthält das Dokument keine weiteren finanziellen Daten oder strategischen Kommentare.

0000924717false00009247172025-08-082025-08-08

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 08, 2025

 

 

Surmodics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Minnesota

0-23837

41-1356149

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

9924 West 74th Street

 

Eden Prairie, Minnesota

 

55344

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 952 500-7000

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.05 par value

 

SRDX

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 2.02 Results of Operations and Financial Condition.

On August 8, 2025, Surmodics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing the Company’s financial results for the quarter ended June 30, 2025. A copy of the full text of the Press Release is furnished as Exhibit 99.1 to this report.

The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

 

 

Description

99.1

 

Press Release dated August 8, 2025

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SURMODICS, INC.

 

 

 

 

Date:

August 8, 2025

By:

/s/ Timothy J. Arens

 

 

 

Timothy J. Arens
Senior Vice President of Finance and Chief Financial Officer

 


FAQ

What form did Surmodics (SRDX) file on August 8, 2025?

Surmodics filed a Form 8-K current report.

What event triggered the SRDX Form 8-K filing?

The company issued a press release announcing financial results for the quarter ended June 30, 2025.

Which exhibit contains Surmodics’ Q3 FY25 press release?

The press release is provided as Exhibit 99.1 to the Form 8-K.

Does the 8-K include actual financial statements or metrics?

No. The filing states results were released but does not include any financial figures within the document.

What is Surmodics’ trading symbol and exchange?

Surmodics trades under SRDX on the Nasdaq Global Select Market.
Surmodics Inc

NASDAQ:SRDX

SRDX Rankings

SRDX Latest News

SRDX Latest SEC Filings

SRDX Stock Data

506.34M
13.74M
3.4%
89.41%
2.32%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
EDEN PRAIRIE